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The development and maintenance of asthma is 
thought to involve the nervous system and the 
immune system1. The regulatory network between 
the immunological events and the neuronal control 
of airway smooth muscle contractility remains to be 
defined2. Neurotrophins represent candidate 
molecules regulating and controlling this cross-talk 
between the immune and nervous system3. 
Neurotrophins are a family of peptides that promote 
survival, growth and differentiation of neurons. 
They include; nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF), and 
neurotrophin-3 (NT-3)4. They are expressed by 
resident lung cells3. Their function in lungs is 
currently poorly understood. They may play an 
important role in the pathophysiology of airway 
hyperresponsiveness during allergic inflammation2. 
The main purposes in developing inflammatory 
indices for asthma are to help early detection and 
differential diagnosis of the disease and further to 
make possible better targeted treatment as well as 
follow up of patients on the basis of objective 
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measurements. The need for simple parameter to 
detect and monitor airway inflammation is obvious 
especially in general practice5. The aim of the 
present study was to investigate the contribution of 
neurotrophins, through measuring one of them 
(BDNF), in asthma exacerbation and severity and to 
study its possible correlation to eosinophils in blood 
and sputum.  
 
METHODS 
This study was conducted on 27 asthmatic children 
recruited from the Pediatric Allergy and 
Immunology Clinic, Children’s Hospital, Ain 
Shams University. They were 18 (66.7%) males and 
9 (33.3%) females, their ages ranged from 5 to 15 
years with a mean age of 9.34 ± 3.57 years. 
Thirty healthy children without history of 
asthma or other atopic conditions and without 
family history of atopy were studied as controls. 
They were 20 (66.7%) males and 10 (33.3%) 
females, their ages ranged from 5 to 15 years with a 
mean age of 9.6 ± 3.66.  
The diagnosis of asthma was based on the 
clinical symptoms and signs of episodic wheezing, 
chest tightness and dyspnea that improved at least 
partially after bronchodilator therapy6. Patients 
were studied within 24 hours of the start of an acute 
asthma exacerbation (defined by increasing cough, 
wheezing, dyspnea and nocturnal symptoms) and 
during remission. The interval between acute 
asthma exacerbation and remission ranged between 
3 and 8 days. 
Patients were classified into 3 groups according 
to the severity of acute asthma exacerbation as 
follows: 
Group I (patients with mild acute asthma 
exacerbation):  It included 9 patients. They were 6 
males and 3 females. Their ages ranged from 5 to 
15 years with a mean age of 8.89 ± 3.72 years. 
Group II (patients with moderate acute asthma 
exacerbation): It included 9 patients, they were 6 
males and 3 females. Their ages ranged from 5 to 
14 years with a mean age of 9.56 ± 3.54 years. 
Group III (patients with severe acute asthma 
exacerbation): It included 9 patients. They were 6 
males and 3 females. Their ages ranged from 6 to 
15 years with a mean age of 9.55 ± 3.84 years. 
All patients in this study were receiving quick-
relief medications to relieve acute broncho-
constriction as oral and or inhaled β2 agonists. In 
addition, 8 patients were receiving inhaled 
corticosteroids for 1-4 years (2 had moderate acute 
exacerbation and 6 had severe acute exacerbation). 
Ten patients were also receiving sustained-release 
theophylline for 1-4 years (2 had moderate acute 
exacerbation and 8 had severe acute exacerbation).  
Methods: 
Patients were subjected to: 
1. Clinical evaluation by history taking laying stress 
on duration of disease, frequency of acute attacks, 
nocturnal symptoms, predisposing factors, drug 
therapy and degree of clinical severity. Clinical 
chest examination was performed to verify 
asthma exacerbation and assess severity. 
2. Classification of the severity of acute asthma 
exacerbation was made according to the protocol 
of the Pediatric Allergy and Immunology Unit, 
Ain Shams University7. In this classification, 
peak expiratory flow rate (PEFR) is included. 
Mini-Wright peak flow meter (Clement Clarke 
International Ltd., Edinburgh, Essex CM202DE, 
England) was used. The PEFR of each patient 
was compared with normal population and % 
predicted was calculated8. 
3. Classification of asthma severity during remission 
into mild intermittent, mild persistent, moderate 
persistent and severe persistent asthma according 
to National Heart, Lung and Blood Institute9. 
4. Complete blood count (CBC) to evaluate the 
number of eosinophils. The patient was 
considered to have elevated blood eosinophilic 
count10 if it was above 400 cells/mm3. 
5. Serum total IgE by enzyme-linked immunoassay 
(ELISA)11 (Pathozyme IgE, Omega Diagnostics 
Limited, UK). 
6. Counting the number of eosinophils in sputum as 
percentage of leucocytes microscopically. 
7. Measurement of serum and sputum brain-derived 
neurotrophic factor (BDNF) level by enzyme-
linked immunosorbent assay (ELISA) method12 
(R and D systems, Oxon OX 14 3 YS, United 
Kingdom). 
Measurements of PEFR, blood eosinophilic count, 
sputum eosinophils percentage and serum and 
sputum BDNF were repeated for all patients during 
remission. 
Blood samples: 
Five ml of venous blood were collected from each 
participated child. Two ml of blood were collected 
into sterile EDTA tubes for CBC assay by Coulter 
(Coulter JT 660, Coulter Electronics Ltd, UK) on 
the same day. The other 3 ml of venous blood were 
withdrawn from each patient and control and left to 
clot for 30 minutes at room temperature and the 
tube was centrifuged at 3000 rpm for 15 minutes. 
The separated serum was stored in sterile aliquots at 
-70°C till time of assay of serum IgE and BDNF. 
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Principle of the serum BDNF assay: 
This assay employed the quantitative sandwich 
enzyme immunoassay technique. A monoclonal 
antibody specific for BDNF had been pre-coated 
onto a microplate. Standards and samples were 
pipetted into the wells and any BDNF present was 
bound by the immobilized antibody. An enzyme-
linked monoclonal antibody specific for BDNF was 
added to the wells. Following a wash to remove any 
unbound antibody-enzyme reagent, a substrate 
solution was added to the wells and color developed 
in proportion to the amount of BDNF bound in the 
initial step. The color development was stopped and 
the intensity of the color was measured. 
 
Sputum BDNF assay: 
Sputum samples were filtered through a two layer 
sterile gauze into sterile plastic vials (Falcon, 
Oxnard, CA), centrifuged at 4°C and 500 x 9 for 10 
minutes. The supernatant was removed and stored 
at -70°C until assay. Sputum obtained was treated 
by adding equal volumes of 0.1% of dithiothreitol 
(sputa-lysine 10%, Gibco BRL, Grandisland, New 
York, USA), followed by equal volumes of 
Dulbecco’s phosphate buffered saline (D-PBS). The 
sample then mixed gently and placed in shaking 
water bath at 37°C for 15 minutes to ensure 
complete homogenization. The sample was 
removed from the water bath periodically for 
further brief gentle mixing. Then centrifugation was 
done at 1500 rpm for 10 minutes. The slide was 
stained with Leishman for differential leucocytic 
count. Eosinophils in sputum are expressed as 
percentage of total leucocytic count. A patient was 
considered to have elevated sputum eosinophils 
percentage if it was above 2% (95th percentile of 
control values) as data distribution was non 
parametric. 
 
Interpretation of BDNF results: 
Patient was considered to have elevated serum or 
sputum BDNF level if it was above the highest cut 
off value (11.5 ng/ml for serum BDNF and 20 
pg/ml for sputum BDNF). These values were 
located above the 95th percentile of the control 
values as data distribution was non-parametric. 
 
Statistical Analysis: 
The results were analyzed by commercially 
available software package (Stat View, Abacus 
Concepts, Inc, Berkley, CA, USA). The data were 
presented as mean and standard deviation (SD). 
Student’s “t” test was used to compare parametric 
data, while Mann Whitney “U” test was used for 
non-parametric data. Pearson correlation coefficient 
“r” was used to determine the relationship between 
different quantitative variables. For all tests, a 




Brain-derived neurotrophic factor levels (in serum 
and sputum) and eosinophilic count (in blood and 
sputum) were significantly elevated in asthmatic 
patients, either when they were studied as a whole 
or subgrouped into mild, moderate and severe, as 
compared to controls (table 1). 
 
Effect of asthma exacerbation on the studied 
laboratory parameters: 
Patients with mild, moderate and severe acute 
asthma exacerbation had significantly higher values 
of serum and sputum BDNF, blood eosinophilic 
count and sputum eosinophils% than the 
corresponding values during remission (table 1). 
Asthmatic patients with severe acute 
exacerbation had significantly higher values of 
sputum BDNF, blood eosinophilic count and 
sputum eosinophils % than the corresponding 
values of patients with moderate and mild 
exacerbation. On the other hand, asthmatic patients 
with moderate acute exacerbation had significantly 
higher value of sputum BDNF than asthmatic 
patients with mild exacerbation. Although blood 
eosinophilic count and sputum eosinophils% in 
patients with moderate asthma exacerbation were 
higher than that of the patients with mild asthma 
exacerbation, yet, this difference was not 
statistically significant. In contrast to sputum BDNF 
levels which increased significantly with the 
disease severity, there were no significant 
differences in serum BDNF levels between patients 
with mild, moderate and severe acute asthma 
exacerbation (table 1). 
 
Variation of the level of the studied asthma 
inflammatory indices in relation to steroid 
therapy: 
Patients who were on steroids (systemic and/or 
inhalation therapy) during acute exacerbation had 
significantly higher values of BDNF (in serum and 
sputum), blood eosinophilic count and sputum 
eosinophils %, than the corresponding values of 
those who did not receive steroids (table 1). 
 
Correlations of serum and sputum BDNF with 
other studied parameters: 
Serum BDNF held significant positive correlations 
with blood eosinophilic count, sputum eosinophil 
percentage, sputum BDNF and serum IgE and 
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significant negative correlation with PEFR during 
asthma exacerbation among all studied groups of 
patients. On the other hand, sputum BDNF had 
significant positive correlations with blood 
eosinophilic count, sputum eosinophils% and 
significant negative correlation with PEFR during 
asthma exacerbation among all studied groups. It 
also had significant positive correlation with serum 
IgE among all asthmatic patients and patients with 
severe exacerbation only (table 2). On the other 
hand, neither serum nor sputum-BDNF showed 
significant correlations with age, height, weight, 
age of onset and duration of disease among all 
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Figure (1): Mean levels of serum BDNF among 

































During exacerbation During remission
Asthma exacerbation
 
Figure (2): Mean levels of sputum BDNF among 
all studied groups. 
 
Sputum BDNF had the highest diagnostic 
sensitivity (100%) followed by serum BDNF 
(92.6%), then blood eosinophilic count (74%) and 
the least sensitivity (55.5%) was of the sputum 
eosinophil percent for diagnosing acute asthma 
exacerbation. Similarly, sputum BDNF had higher 
sensitivity for diagnosing mild and moderate 
exacerbations (100% for both) than serum BDNF 
(88.9% for both), blood eosinophilic count (44.4% 
for mild exacerbation and 77.7% for moderate 
exacerbation) and sputum eosinophil percent 
(44.4% for mild exacerbation and 55.5% for 
moderate exacerbation). In severe exacerbation, the 
sensitivities of sputum and serum BDNF and blood 
eosinophilic count were equal (100%) and were 
higher than that of sputum eosinophil percent 
(66.7%). Sputum BDNF has much higher 
sensitivity for the differentiation of mild from 
moderate acute asthma exacerbations (100%), mild 
from severe exacerbations (100%) and moderate 
from severe exacerbation (88.9%) than did serum 
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Figure (3): Mean levels of blood eosinophilic 






























During exacerbation During remission
Asthma exacerbation
 
Figure (4): Mean levels of sputum eosinophils % 
among all studied groups.





Table (1): Variation of serum and sputum BDNF levels and blood and sputum eosinophil count with 
asthma activity and severity. 
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Table (2): Correlations between serum and sputum BDNF and other studied laboratory 
parameters during asthma exacerbation 
Variable 
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(n = 9) 
Serum BDNF 92.6% 88.9% 88.9% 100% 
Sputum BDNF 100% 100% 100% 100% 
Blood eosinophilic 
count 74.1% 44.4% 77.7% 100% 
Sputum 
eosinophils% 55.5% 44.4% 55.5% 66.7% 
Sensitivity = True positive X 100 True positive + false negative 
True positive = Patients with acute asthma exacerbation and elevated marker level. 




Both serum and sputum BDNF were significantly 
higher in asthmatic patients than controls during 
acute exacerbation, either when they were studied 
as a whole or subgrouped as mild, moderate and 
severe. Similar findings regarding serum BDNF 
were reported by Virchow et al.12 who suggested 
that BDNF participates in the pathophysiology  of 
allergic diseases including asthma.  
To date, no available data regarding sputum 
BDNF levels in asthmatic children have been 
reported to be compared with our results. Virchow 
et al.12  reported increased levels of neurotrophins  
(NGF, BDNF and NT-3) in the bronchoalveolar 
lavage fluid from patients with asthma after 
segmental allergen provocation meaning that 
neurotrophins are produced endobronchially 
following allergen provocation, suggesting their 
contribution to the pathogenesis of asthma. 
Investigations of the inflammatory response of 
airways to allergen challenge in asthma has usually 
relied on invasive techniques such as bronchial 
biopsy and bronchoalveolar lavage. The less 
invasive technique of sputum induction offers an 
alternative to invasive techniques2.  
Renz3 mentioned that neurotrophins are 
elevated in asthmatic patients as they play an 
important role in the pathophysiology of asthma in 
several ways. The predominant effect on peripheral 
nerves innervating the lungs is described by the 
term “neuronal plasticity” which is defined as 
qualitative and / or quantitative changes in the 
functional activity and capacity of peripheral 
neurons leading to heightened autonomic reflex 
activity. These neurons control development of 
airway hyperresponsiveness and acute 
inflammatory responses resulting in the concept of 
“neurogenic inflammation” due to increased 
production of neuropeptides and tachykinins. 
Neurotrophins also exhibit profound effects on 
immune cells residing in airways and lung tissue. 
These effects are described by the term 
Salama et al. 
108 
“immunological plasticity”13. Thus, BDNF links 
pathologic events in bronchial asthma to 
dysfunctions of the immune and nervous system3. 
The traditional cellular sources of 
neurotrophins, including BDNF, under 
physiological conditions are primarily nerve-
associated cells such as glial cells, Schwann cells or 
fibroblasts and neurons themselves3. Braun et al.13 
mentioned that in inflammatory processes, BDNF is 
also produced by a wide range of hematopoietic 
cells including mast cells, macrophages and T cells. 
In addition, airways epithelium constitutively 
expresses BDNF. Thus, BDNF may be an 
inflammatory product that links bronchial 
hyperreactivity to the inflammatory processes 
occurring in bronchial asthma. Wider-scale studies 
are needed to prove this argument.  
BDNF liberation is important for the 
development of bronchial hyperresponsiveness in 
asthma by neurogenic inflammation. This pathway 
could be triggered by immune cells with the 
potential to release neurotrophins in allergic 
inflammation. Vice versa, immune cells are widely 
influenced by BDNF which is able to induce 
degranulation and differentiation of mast cells, the 
key cells of the early allergic response14. 
In our study, although sputum and serum 
BDNF correlated positively with the disease 
severity as evidenced by their significant negative 
correlation with PEFR, yet sputum BDNF 
correlated better with disease severity as evidenced 
by its significant elevation in patients with acute 
severe asthma exacerbation as compared to those 
with mild and moderate acute asthma exacerbations 
and also in patients with moderate acute asthma 
exacerbations as compared to those with mild acute 
asthma exacerbation. So, further studies are 
warranted to determine cut-off values for sputum 
BDNF which may aid in the classification of 
asthma severity. 
Although serum and sputum BDNF levels 
decreased significantly during asthma quiescence, 
yet these levels were still significantly higher than 
that of controls. This finding denotes the underlying 
and ongoing neurogenic inflammation with release 
of neurotrophins such as BDNF. The latter may 
result in airway inflammation and hyperactivity that 
may be provocated easily at any time. This 
underscores the importance of clinical examination 
alone as a guide of subsidence and control of 
asthma exacerbation and highlights the importance 
of searching for inflammatory markers of bronchial 
asthma such as BDNF for objective measurement of 
asthma quiescence and guidance of proper response 
to asthma therapy. 
The duration of illness in the present study did 
not influence serum and sputum BDNF levels 
neither did the age of the child nor the gender. The 
small sample size in the present study did not allow 
for proper analysis of epidemiological data.  
Eosinophilia measured both in the peripheral 
blood and in the airway secretions is a characteristic 
feature of asthma. Furthermore the severity of the 
eosinophilia is correlated with objective markers of 
asthma severity such as lung function15. This was 
also the case in our series. The asthmatic patients 
had significantly higher blood eosinophilic counts 
and sputum eosinophils% than controls. Similar 
findings were reported by previous studies16-18. In 
our study, blood and sputum eosinophilic counts 
were significantly higher in patients with severe 
asthma exacerbation than those with mild and 
moderate exacerbations. Jang et al.19 similarly 
reported increased sputum eosinophil counts in 
severe or life threatening asthma than in mild to 
moderate asthma. Although their levels in patients 
with moderate exacerbation seemed higher than 
those with mild exacerbation, yet this difference 
was not statistically significant. El-Gamal et al.16 
reported that there was a lack of significant 
difference in blood eosinophilic percentage between 
patients with moderate and those with severe 
asthma exacerbation. They suggested that priming 
of eosinophils occurs in all asthmatics irrespective 
of the severity of bronchospasm.   
We found that both serum and sputum BDNF 
showed significant positive correlations with blood 
eosinophilic count in one hand and with sputum 
eosinophilic percent values in the other. This may 
suggest that BDNF has eosinophil chemotactic 
effect and this could be one of the ways by which it 
exerts its airway inflammatory effect, or 
alternatively it may represent one of the 
components of the late phase inflammatory 
response.  
The high sensitivity of BDNF (both in serum 
and sputum) for asthma exacerbation together with 
its significant positive correlation with asthma 
severity and eosinophilic count in blood and sputum 
denote that this neurotrophin reflects the 
inflammatory processes in bronchial asthma even in 
mild exacerbations. 
Corticosteroid-treated asthmatic patients had 
significantly higher eosinophilic count (in blood 
and sputum) and BDNF levels (in blood and 
sputum) than non-corticosteriod-receivers. This was 
surprising because corticosteroids were supposed to 
control inflammation of the airways with 
subsequent decrease in the levels of inflammatory 
indices. However, this could be explained by the 
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fact that corticosteroids were used mostly by 
inhalation in patients categorized to have moderate 
or severe persistent asthma whose symptoms are 
not well controlled. So, this finding might actually 
be a reflection of disease severity. Further wide-
scale studies are warranted to investigate the 
variation in BDNF levels according to the mode of 
therapy in bronchial asthma.  
In conclusion, BDNF plays a role in the 
evolution of asthma exacerbation and its levels 
(especially in the sputum) reflect the degree of the 
severity of asthma exacerbation and the ongoing 
inflammatory process during asthma quiescence. 
This highlights the importance of BDNF as an 
inflammatory marker detecting both the evolution 
and the control of asthma exacerbation. Therefore, 
it might represent an objective guide of treatment 
efficacy. Trials with specific BDNF receptor 
antagonists or synthesis inhibitors are required as 
BDNF may prove to be a reasonable target for a 
new therapy in the future.  In addition, studies 
concerning the relation between BDNF and 
bronchial hyperreactivity are also required as it may 
be a link between hyperreactivity and the 
inflammatory process in bronchial asthma. 
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